Lanraplenib succinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib succinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
Ribociclib succinate hydrate is a highly specific CDK4/6 inhibitor (IC50s: 10 nM and 39 nM, respectively). It also is over 1,000-fold less potent against the cyclin B/CDK1 complex.
m-PEG-Succinimidyl Succinate (MW 5000) is a polyethylene glycol (PEG)-based linker featuring succinimidyl succinate functionality, primarily applied in the synthesis of proteolysis-targeting chimeras (PROTACs)[1].